Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: a multicenter, randomized, double-masked comparative study.
OBJECTIVE
To compare the effects of topical nipradilol and timolol on the visual field in Japanese normal-tension glaucoma (NTG) patients.


METHODS
We enrolled 146 NTG patients. At baseline, age, intraocular pressure (IOP), and mean deviation (MD) by the Humphrey field analyzer were 47.6 (SD 8.5), 14.2 (1.7) mmHg, and -4.5 (3.0) dB. Seventy-two patients were randomly assigned to the 0.25% nipradilol group and 74 patients to the 0.5% timolol ophthalmic solution group twice daily for the 3-year study period. The Humphrey full-threshold 30-2 visual field test was performed every 6 months. The primary end point was the nonparametric O'Brien summary score (sum of the ranks of six slopes calculated from the average of the total deviation in each cluster) in each patient. The secondary analyses were differences in the MD slope, average of the total deviation in each cluster, the corrected pattern standard deviation (CPSD), and the time course of IOP.


RESULTS
No significant intergroup differences were found in baseline characteristics, or in the parameters of the primary and secondary analyses. In both groups, central superior clusters showed negative slopes and IOP decreased by about 1 mmHg from baseline.


CONCLUSIONS
No significant difference in visual field performance or IOP reduction was seen between the nipradilol and timolol groups.
Araie
Makoto
M
Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan. araie-tky@umin.ac.jp.
Shirato
Shiroaki
S
Yotsuya-Shirato Eye Clinic, Shinjuku-ku, Tokyo, Japan.
Yamazaki
Yoshio
Y
Department of Ophthalmology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.
Kitazawa
Yoshiaki
Y
Akasaka Kitazawa Eye Clinic, Minato-ku, Tokyo, Japan.
Ohashi
Yasuo
Y
Department of Biostatistics, School of Public Health, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011412:Propanolamines / Q000008:administration & dosage*; D013999:Timolol / Q000008:administration & dosage*; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D058609:Visual Field Tests; D014794:Visual Fields / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D011412:Propanolamines; D013999:Timolol; C036089:nipradilol
Ophthalmology. 2001 Feb;108(2):247-53
11158794
Ophthalmology. 2002 Apr;109(4):766-70
11927438
Drug Metab Dispos. 2002 Apr;30(4):421-9
11901096
Biometrics. 1984 Dec;40(4):1079-87
6534410
Surv Ophthalmol. 1994 Jul-Aug;39(1):23-42
7974188
Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30
12049575
Surv Ophthalmol. 1999 Jun;43 Suppl 1:S162-70
10416759
Am J Ophthalmol. 1998 Oct;126(4):498-505
9780094
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4041-8
15505054
Control Clin Trials. 1988 Dec;9(4):327-44
3203524
Arch Int Pharmacodyn Ther. 1983 Mar;262(1):132-49
6135395
Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3243-50
12356831
J Glaucoma. 1999 Apr;8(2):117-23
10209728
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):688-94
11222528
Br J Ophthalmol. 2000 Mar;84(3):293-9
10684841
Arzneimittelforschung. 2006;56(11):729-34
17220049
Brain Res. 1997 Mar 14;751(1):113-23
9098574
Ophthalmic Res. 2002 Nov-Dec;34(6):331-7
12483019
J Glaucoma. 2001 Apr;10(2):121-8
11316094
Ophthalmology. 2001 Nov;108(11):1943-53
11713061
Brain Res. 2002 Dec 20;958(1):10-9
12468025
Eye (Lond). 2004 Oct;18(10):984-9
15037889
Am J Ophthalmol. 1998 Oct;126(4):487-97
9780093
Am J Ophthalmol. 2000 Oct;130(4):429-40
11024415
J Ocul Pharmacol Ther. 2001 Jun;17(3):235-48
11436944
Ophthalmology. 1982 Mar;89(3):268-79
7088510
Arch Ophthalmol. 1977 Jul;95(7):1173-5
880074
Jpn J Ophthalmol. 2003 Mar-Apr;47(2):199-207
12738555
Brain Res. 2007 May 7;1148:28-37
17368577
Eur J Pharmacol. 2002 Oct 11;452(3):263-8
12359266
Ophthalmology. 2004 Nov;111(11):2117-25
15522380
Graefes Arch Clin Exp Ophthalmol. 1989;227(5):408-12
2806924
Invest Ophthalmol Vis Sci. 1998 Apr;39(5):736-43
9538880
Am J Ophthalmol. 1989 Nov 15;108(5):485-95
2683792
Exp Eye Res. 2005 Apr;80(4):501-7
15781277
J Glaucoma. 2002 Jun;11(3):231-8
12140401
Curr Eye Res. 2002 Feb;24(2):114-22
12187483
Arzneimittelforschung. 2006;56(12):820-5
17260669
Ophthalmology. 1996 Feb;103(2):283-8
8594515
Arch Int Pharmacodyn Ther. 1985 Nov;278(1):61-71
2869737
Arch Ophthalmol. 2002 Oct;120(10):1268-79
12365904